Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer

INTRODUCTION: The mutation rate of T790M might change the effective therapeutic sequence of EGFR tyrosine kinase inhibitors (TKIs). This simulation estimates the T790M positivity rate required for first-line first- or second-generation EGFR TKI to exceed overall progression-free survival (PFS) of fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Haratake, Naoki, Misumi, Toshihiro, Yamanaka, Takeharu, Seto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474446/
https://www.ncbi.nlm.nih.gov/pubmed/34589964
http://dx.doi.org/10.1016/j.jtocrr.2020.100085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474446/
https://www.ncbi.nlm.nih.gov/pubmed/34589964
http://dx.doi.org/10.1016/j.jtocrr.2020.100085

Ejemplares similares